Physician profile
Jennifer Clair Kitkowski
NPI 1417598905
$2,999.16
in general payments reported to CMS, 2019-2025
30 companies · $2,283 in 2025
The $2,283 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $144 · 2022: $28.92 · 2023: $96.19 · 2024: $447 · 2025: $2,283.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,650 · Education: $177.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,649.61 |
| Education | $176.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $361.10 | 2025 | Talvey, Tecvayli, Darzalex |
| Astrazeneca Pharmaceuticals LP | $345.96 | 2025 | Imfinzi, Enhertu, Lynparza |
| Novo Nordisk INC | $234.23 | 2021-2024 | Wegovy |
| Glaxosmithkline, LLC. | $232.52 | 2023-2025 | Arexvy, Shingrix, Ojjaara |
| Incyte Corporation | $222.59 | 2025 | Monjuvi, Jakafi, Monjuvi |
| Daiichi Sankyo INC. | $211.95 | 2025 | Enhertu, Datroway, Vanflyta |
| Abbvie INC. | $153.44 | 2022-2024 | |
| Astellas Pharma US INC | $148.66 | 2024-2025 | Veozah, Vyloy |
| Pharmacosmos Therapeutics INC. | $142.80 | 2025 | Cosela, Monoferric |
| Sobi, INC | $127.81 | 2025 | |
| Pharmaessentia USA Corporation | $101.05 | 2025 | Besremi |
| Genmab U.S., INC. | $89.76 | 2025 | Epkinly |
| Regeneron Healthcare Solutions, INC. | $71.99 | 2025 | Libtayo, Lynozyfic |
| Celgene Corporation | $59.33 | 2025 | Reblozyl |
| Lilly USA, LLC | $55.24 | 2025 | Verzenio, Jaypirca |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $51.01 | 2025 | |
| Merck Sharp & Dohme LLC | $45.38 | 2025 | Keytruda, Keytruda Qlex, Lynparza |
| Caris Mpi, INC. | $39.33 | 2025 | Mi Cancer Seek |
| E.R. Squibb & Sons, L.L.C. | $38.76 | 2025 | |
| Novartis Pharmaceuticals Corporation | $37.65 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $32.40 | 2025 | Advate |
| Immunocore Limited | $27.95 | 2025 | Kimmtrak |
| Emd Serono, INC. | $25.29 | 2025 | |
| Geron Corporation | $23.11 | 2025 | Rytelo |
| Genentech USA, INC. | $22.27 | 2021 | |
| Adc Therapeutics America, INC. | $21.45 | 2025 | |
| Myriad Genetic Laboratories, INC. | $20.97 | 2025 | Precisetumor |
| Exelixis INC. | $19.75 | 2025 | Cabometyx |
| Pfizer INC. | $17.98 | 2025 | |
| Array Biopharma INC | $17.43 | 2025 | Mektovi, Braftovi, Tukysa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Kitkowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.